Navigation Links
ERT Reports Second Quarter 2011 Operating Results
Date:8/1/2011

205 29   Stock option income tax benefit2 2   Repurchase of common stock for treasury-   (46)Net cash provided by financing activities23,217 595 Effect of exchange rate changes on cash(2,553),817 Net (decrease) increase in cash and cash equivalents(46,475),258 Cash and cash equivalents, beginning of period8,979 30,343 Cash and cash equivalents, end of period $
22,504 $
31,601 eResearchTechnology, Inc. and SubsidiariesReconciliation of GAAP to Non-GAAP Information (in thousands, except per share amounts)(unaudited)Three Months EndedSix Months EndedJune 30,   2010

March 31, 2011

June 30,   2011June 30,
2010

June 30,
2011Net revenues$
29,096

$
41,699

$
42,849$
50,964

$
84,548Reconciliation of GAAP to Non-GAAP gross margin:GAAP gross margin$
5,814

$
8,420

$
,045$
27,572

$
34,465Amortization of acquired intangibles and other assets833

1,878

1,970833

3,848Non-GAAP gross margin$
,647

$
20,298

$
8,015$
28,405

$
38,313Non-GAAP gross margin percentage57.2%

48.7%

42.0%55.7%

45.3%Non-GAAP gross margin percentage is calculated by dividing non-GAAP gross margin by net revenues-Reconciliation of GAAP to Non-GAAPoperating income:GAAP operating income$
,051

$
5,354

$
2,570$
3,798

$
7,924Amortization of acquired intangibles and other assets833

1,878

1,970833

3,848Acquisition and integration related costs3,840

-

-4,581

-Non-GAAP operating income$
5,724

$
7,232

$
4,540$
9,212

$
,772Non-GAAP operating income margin percentage19.7%

17.3%

10.6%18.1%

13.9%Non-GAAP operating income margin percentage is calculated by dividing non-GAAP operating income by net revenues-Reconciliation of GAAP to Non-GAAP net income:GAAP net income$
826'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
(Date:5/21/2013)... 2013, Paris, France: One-year results from SOURCE XT ... (TAVI) registries to-date reported today at EuroPCR 2013 ... high rates of device success for all access approaches, ... Post-Approval Study followed up 2688 consecutively enrolled patients (mean ... heart valve at 93 centres in 17 countries between ...
(Date:5/21/2013)... May 21, 2013 According to a May ... the Use of Botox,” Botox injections have become ... approval in 2002 (Go to goo.gl/8iYbD). Although it is mostly ... with men. The injection makes facial wrinkles less visible by ... last for about three months. This means that people who ...
(Date:5/21/2013)... May 21, 2013 Phoseon Technology will ... at the 20th Annual IMI European Ink Jet Conference ... market leader, Phoseon continues to invest in product development ... adoption of UV LED curing in printing applications. ... on the market offering both air cooled and water ...
(Date:5/21/2013)... MedMar Healing Center announces their participation in the ... Twenty-eight businesses, including MedMar Healing Center, doctors, and clubs, are ... is to raise food to help area kids who have ... recent years. , “We like being able to give ... Douglas Chloupek of MedMar Healing Center. “Taking part in the ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3
... problems faced by youngsters with the disease , THURSDAY, July ... more likely to be overweight than those without the disease, ... The finding is from a major study that explored the ... a less common form of the disease that usually shows ...
... the launch of (RED)ZONES at the first U2 360 Degrees concert ... rapturous sold out crowd of 90,000 fans. , , ... will be present throughout the U2 tour. The tickets for ... the ticket sales going to the Global Fund to help fund ...
... 2 "If recent reports of DEA intervention are accurate, ... Diversion unit, and it won,t end there. The pharmacists who ... as will everyone whose name is associated with any of ... , Mr. Mullin won full federal jury acquittal at ...
... DUBLIN, Ohio, July 2 Cardinal Health today announced that ... effective upon the completion of the planned spinoff of CareFusion ... board for personal reasons after 22 years of service to ... Downey is the former chairman and chief executive officer of ...
... committee,s recommendations to the U.S. Food and Drug Administration (FDA) to put ... from the American Academy of Pain Medicine (AAPM), ... The American Academy of Pain Medicine (AAPM), which ... Pain Medicine, supports the safe and responsible, ...
... plug a Percocet-Vicodin gap, experts say, , THURSDAY, July 2 ... which a U.S. health advisory panel has urged, would not ... , The reason, they say, is that other options are ... made its recommendation Tuesday. It followed the release in May ...
Cached Medicine News:Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3Health News:DEA Will Play Hardball in Investigating Michael Jackson's Doctors 2Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 2Health News:If 2 Painkillers Are Banned, What Next? 2Health News:If 2 Painkillers Are Banned, What Next? 3Health News:If 2 Painkillers Are Banned, What Next? 4
... excellent choice for orthopedic procedures. ... to 24" for the surgeon's ... quickly attach to any O.R. table. ... C-Arm access and stability. Optional ...
... and ultra versatile model angulates for ... adjust the height of the support ... single post, or double tee foot. ... physician comfort and stability. A convenient ...
... torso and leg sections of ... simultaneously lift body and legs. ... raises and lowers legs individually ... A wide range of adjustment ...
... The PROfx elevates the surgical table to ... by providing the perfect table complement for ... an integral role in the surgical process, ... skill of the surgeon to minimize the ...
Medicine Products: